10:40 AM EDT, 09/18/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lift our target price to $216 from $190, 16.8x our 2026 EPS, a discount to IQV's five-year historical forward P/E average of 21.0x. We maintain our 2025 at $11.96 and our 2026 EPS view at $12.88. We think it is time to be selective in the Life Science Tools and Services sub-industry as we see continue to see elevated policy risks amid a fluid tariff environment. We favor well-diversified firms with a strong track record of execution and innovation and see IQV as well positioned in the space. We think IQV benefits from its diversification with significant earnings coming from health care technology and analytics as well as contract research and commercialization services. We expect these industries to experience long-term demand growth as increased efficiency in health care delivery becomes a greater focus. Amid a tough operating environment, IQV kept a solid book-to-bill ratio of 1.12x in Q2 with $2.5B in net new bookings, indicating a healthy pipeline, which was encouraging, in our view.